An estimated 30 million people in Europe face the complex challenges of a rare disease. For these individuals and their families, the path to diagnosis and treatment is often a protracted journey hindered by fragmented research, small patient populations, and significant economic barriers. However, a collaborative model is demonstrating a powerful way forward. Strategic rare disease partnerships, particularly those fostered under Europe’s Innovative Medicines Initiative (IMI) and Innovative Health Initiative (IHI), are systematically addressing these systemic hurdles. This article examines a recent EFPIA View and how these consortia are building a more sustainable and effective innovation ecosystem for conditions that have long been neglected.

Addressing the Core Bottlenecks in Rare Disease Research

The traditional model of drug development struggles profoundly when applied to rare diseases. Key structural problems include the scarcity of patients for clinical trials, a frequent lack of understanding of disease progression, and diagnostic delays averaging five to seven years. Consequently, developing therapies becomes a high-risk economic proposition. Public-private partnerships are designed to confront these issues directly by pooling resources, expertise, and data across sectors. Their goal is to construct shared solutions that de-risk innovation and benefit the entire ecosystem, from researchers to patients.

Redesigning Clinical Trials for Small Populations

A primary obstacle is generating robust evidence from very small patient groups. IMI/IHI projects are creating the necessary methodologies and infrastructure to make this possible.

The EU-PEARL project established a framework for platform trials in Europe. This model allows multiple treatments for related conditions to be tested under a single, adaptive protocol, greatly improving efficiency. Its real-world value is clear; the Children’s Tumor Foundation is now applying this framework for a platform trial in neurofibromatosis.

For the most challenging ultra-rare conditions, the RealiseD project co-creates practical trial ‘playbooks’ with regulators, health technology assessment bodies, and patient groups. This alignment ensures study designs are not only scientifically rigorous but also meet the evidence requirements for later approval and reimbursement decisions.

Accelerating Diagnosis Through Technology

Shortening the diagnostic odyssey is a critical first step towards effective care. The Screen4Care project employs a dual technological strategy. First, it advances genetic newborn screening to identify conditions at the earliest stage. Second, it develops digital tools, including an AI-supported symptom checker, to help flag potential rare disease cases in the wider population. This combined approach aims to illuminate diagnostic ‘white spots’ and bring answers to patients and families much sooner.

Creating Unified Patient-Centred Data Systems

Fragmented data is a major barrier to understanding rare diseases. Projects are working to integrate isolated information sources into cohesive platforms. For example, the PaLaDIn project focuses on neuromuscular diseases, harmonising data from registries, wearable devices, and patient-reported outcomes. This creates a richer, longitudinal picture of disease that can support therapy development and generate robust real-world evidence, a factor increasingly considered by decision-makers.

Integrating the Patient Perspective into Development

Ensuring research reflects what matters most to patients is vital. The PREFER project delivered concrete recommendations on capturing patient preferences regarding treatment benefits and risks. This work provides a framework for industry and regulators to systematically incorporate these views into drug development and assessment. Meanwhile, projects like RealiseD and paediatric network C4C involve patients and families directly in designing trials, ensuring they are feasible, ethical, and focused on meaningful outcomes.

Implications for Healthcare Strategy and Policy

The impact of these collaborative rare disease partnerships extends far beyond individual research projects. They offer strategic lessons for healthcare decision-makers.

For policymakers, the outputs—such as new trial methodologies and data standards—support a more predictable and adaptive regulatory environment. Sustained investment in these partnerships strengthens Europe’s capacity for complex health research. For health economists and payers, the generation of higher-quality evidence enables more informed assessments of a treatment’s value. Furthermore, the patient preference data generated helps align value definitions with what patients truly need.

For the pharmaceutical industry, the shared infrastructure and pre-competitive tools reduce duplication of effort and lower the risk of entering rare disease development. This makes pursuing therapies for even the rarest conditions a more viable strategic pursuit. Ultimately, these consortia demonstrate that overcoming systemic challenges in healthcare requires a collective effort. By continuing to support and refine the model of public-private collaboration, Europe can ensure a more resilient and responsive innovation pathway for all rare disease patients.

Reference

https://www.efpia.eu/news-events/the-efpia-view/efpia-news/impact-of-innovative-medicineshealth-initatives-projects-on-rare-diseases/